Author

L. V. Sequist

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. N. Hata· 2 shared M. S. Lawrence· 2 shared Z. Piotrowska· 2 shared A. Abbasi· 1 shared A. Bardia· 1 shared A. Deshpande· 1 shared A. Langenbucher· 1 shared A. Mishra· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. N. Hata

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product

A. Mishra, S.-B. Huang, T. Dubash, R. Burr, B. S. Wittner, Q. E. Cunneely, V. R. Putaturo, A. Deshpande, E. Antmen, K. A. Gopinathan, K. Otani, Y. Miyazawa, J. E. Kwak, S. Y. Guay, J. Kelly, , M. Toner

This study uses high-throughput microfluidic technology to enrich CTCs from large blood volumes, enabling detailed molecular and morphological analysis of tumor cells in metastatic cancer patients.

bioRxiv · Mar 13, 2024 · PreprintBioengineering

APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer

H. Isozaki, A. Abbasi, N. Nikpour, A. Langenbucher, W. Su, M. Stanzione, H. Frisco-Cabanos, F. M. Siddiqui, N. Phan, P. Jalili, S. Oh, D. Timonina, S. Bilton, M. Gomez-Caraballo, H. L. Archibald, , A. N. Hata

This study shows that APOBEC3A mutagenesis driven by targeted therapies promotes drug resistance in non-small cell lung cancer.

bioRxiv · Jan 20, 2021Cancer Biology

Modeling Resistance and Recurrence Patterns of Combined Targeted- Chemoradiotherapy Predicts Benefit of Shorter Induction Period

D. M. McClatchy, H. Willers, A. N. Hata, Z. Piotrowska, L. V. Sequist, H. Paganetti, C. Grassberger

The paper develops a bio-mathematical model to simulate recurrence patterns in lung cancer under combined targeted therapy and CRT, showing that long induction periods may reduce the effectiveness of adjuvant therapy.

bioRxiv · Dec 2, 2019Biophysics